First Republic Investment Management, Inc. Savara Inc Transaction History

First Republic Investment Management, Inc.

$34.7 Billion
Q3 2023

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2021 Nov 12, 2021	SELL	$1.18 - $1.64 $30,680 - $42,640	-26,000 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$1.17 - $2.33 $30,419 - $60,580	26,000 New	26,000 $54,000

Others Institutions Holding SVRA

# of Institutions

128

Shares Held

158M

Call Options Held

67.6K

Put Options Held

29.4K

Nea Management Company, LLC Timonium, MD

24.5M
Shares

$78.3 Million
7.93% of portfolio
Bain Capital Life Sciences Investors, LLC Boston, MA

14.6M
Shares

$46.6 Million
11.08% of portfolio
Tcg Crossover Management, LLC Palo Alto, CA

12.4M
Shares

$39.6 Million
6.8% of portfolio
Wellington Management Group LLP Boston, MA

8.62M
Shares

$27.6 Million
0.01% of portfolio
Frazier Life Sciences Management, L.P. Menlo Park, CA

8.16M
Shares

$26.1 Million
1.86% of portfolio

View Full List

About Savara Inc

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $365M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

More about SVRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Republic Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Republic Investment Management, Inc. with notifications on news.

Account